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ABSTRACT
Pathogens continue to evolve mechanisms of avoiding efforts to 
control their spread. Treatment with exogenous antimicrobials often occurs 
after the pathogen has reproduced extensively in the host. In the case of 
mammals, the immune system may not be fully mobilized for 72 h  after the 
detection of foreign antigen. However, within 24 h of presentation of 
antigen by antigen-presenting cells to resting thymus-derived lymphocytes 
IL2 is produced. A class of broad spectrum antimicrobial peptides which 
constitute a major component of the insect immune system has been 
described and characterized. Called "cecropins", they are relatively non-toxic 
to norm al cells from multicellular organisms but are toxic to a wide range of 
bacteria, protozoa, and fungi as well as infected and abnormal cells. The 
experiments presented here describe the construction of a plasm id vector 
and transcription of mRNA for a cecropin-class synthetic lytic peptide, Shiva 
1, under control of the mouse IL2 prom oter/enhancer and linked to the IL2 
signal sequence. Twenty-eight lines of transgenic mice were produced by 
pronuclear injection of a BamHI fragment containing from -593 to +110 of 
the 5' flanking region of mouse interleukin 2 gene including the peptide 
signal sequence, Shiva 1, and the SV40 polyadenylation signal and splice 
site. By a reverse-transcription polymerase chain reaction (RT-PCR) assay, it 
was determined that two lines of transgenic mice were produced whose 
spleen derived lymphocytes could be induced to transcribe and mature 
mRNA for Shiva 1 by exposure to 3.25 (ig/m l of concanavalin A. In
v
addition, one of the lines showed evidence of in vivo expression. Since the 
controlling regions of the IL2 enhancer and amino acid sequence of the 
signal peptide are highly conserved among humans, mice, cattle, and sheep, 
it is likely that this recombinant gene will function in a variety of mammals. 
Studies to assess immune system enhancement of the mice are ongoing.
INTRODUCTION
Finding more efficient ways of combating disease both in hum ans and 
the plants and animals we depend upon for food and fiber has been and is a 
prim ary concern of biological research. Pathogens repeatedly elude 
treatm ents necessitating constant innovation. Bacteria once susceptible to 
compounds such as sufamethazine, penicillin, and streptomycin are 
evolving resistant strains. Concerted efforts by world wide medical 
researchers have had little success in combating viral infections once they 
become established, with the notable exceptions of the deoxynucleotide 
analogs such as 3'-azidothymidine (AZT) against the hum an 
immunodeficiency virus and 9-[[Hydroxy-l-(hydroxymethyl)ethoxy]methyl]- 
guanine (gancyclovir) and acycloguanosine (acyclovir) against herpes virus. 
Likewise, cancer remains difficult to treat successfully. Combinations of 
surgery, radiation therapy, and hightoxic chemicals are typically used. 
However, they often cause severe damage to healthy tissue seading to 
undisirable side effects and are far from 100% effective.
One problem with treatment is that the disease is often not detected 
until after the organism or malignant cell has m ultiplied extensively in the 
host. By then, the host's own genetically coded immune defenses have been 
m ustered for the battle and, in the case of mammals, the first line is engaged. 
Lymphocytes and macrophages are concentrated at the site of challenge and 
the first signals in the immune system activation pathways have been sent 
and received.
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Genetic engineers are investigating methods for increasing the 
effectiveness of the natural immune system. Antimicrobial compounds 
genetically delivered to the pathogen when it is first detected by the host's 
immune system would bolster resistance. In the case of mammals, the ideal 
systems in which to have expression of an antimicrobial w ould be the blood 
and lymph.
It was the goal in this set of experiments to design and implement 
such a system. The scheme relies on two basic components. The first is a 
synthetic antimicrobial peptide of the cecropin class, Shiva 1. The cecropins 
have been shown to be toxic to a broad spectrum of pathogens and some 
transformed cells. The second is the promoter and enhancer of the 
endogenous lymphokine, interleukin 2, normally produced by helper 
thymus-derived lymphocytes (helper T cells) in response to imm une system 
challange.
REVIEW OF THE LITERATURE
INTERLEUKIN 2 
Interleukin 2 (IL2) is an important signaling protein whose 
production in helper T lymphocytes (Fitch, 1992) peaks within 24 hours (h; 
Fletcher and June, 1992) of the presentation of a specific foreign antigen by 
antigen presenting cells in the mammalian imm une system. The prim ary 
role of IL2, within the present understanding, is as a growth factor 
supporting proliferation of cytotoxic T cells, natural killer (NK) cells, helper 
T cells, bone m arrow derived lymphocytes (B cells), macrophages, and 
lymphokine-activated killer (LAK) precursors in a paracrine and autocrine 
fashion (Delves and Roitt, 1992). Activated T cells conduct the functions of 
cell-mediated immunity and a subset, helper T cells, secrete IL2 necessary for 
B cell production of soluble antibody, hence, humoral immunity. M ature 
resting T cells continuously circulate from lymphoid tissues (i.e., spleen, 
lym ph nodes) via efferent lymphatics into blood and non-lym phoid tissue 
then back to lymphoid tissue via the afferent lymphatics (Scollay, 1992).
This wide circulation exposes even isolated pockets of invading organisms 
to a large T cell pool and maximizes the possibility of triggering specific 
imm unity dom inated by cytotoxic T cells and B cells.
Activation of T cells starts when antigen processed by B cells (Pike, 
1992) or macrophages is displayed in conjunction w ith major 
histocompatability complex (MHC) class I or II. Binding of this complex to 
the T cell receptor complex and simultaneous interaction of antigen
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presenting cell surface protein CD58 with T cell CD2, MHC with T cell CD4 
and antigen presenting cell B7/BB-1 with T cell CD28 initiates a complex 
chain of events leading to secretion of IL2 by helper T cells. The chain begins 
w ith the activation of T cell receptor-associated tyrosine kinase, which 
activates phospholipase C. Phospholipase C cleaves phosphatidylinositol- 
4,5-bisphosphate into a sugar, diacylglycerol, and inositol-1,4,5-trisphosphate 
(IP3). The IP3 binds to a receptor inducing the release of intracellular calcium 
ion (Ca+2). Diacylglycerol acts in conjunction with Ca+2 and phospholipid to 
activate protein kinase C (Fletcher and June, 1992). These intercellular 
messengers and T cell receptor and CD2 binding are required for IL2 
induction, however, a third signal which involves interaction of T cell 
surface protein CD28 with protein B7/BB-1 from the antigen presenting cell, 
results in optimal transcription of IL2 (Fraser et al, 1991; Granelli-Piperno 
and Nolan, 1991). Protein kinase C also functions to dow n regulate the 
activation cascade by deactivating phospholipase C and down-regulating 
both phosphotyrosine phosphatase activity and a required transcription 
activating protein, AP-1 (Jain et al., 1992b).
While T cell activation in general appears to be mostly independent 
of de novo protein production (Taniguchi, 1988), Granelli-Peperno and 
Nolan (1991) reported that two factors required for initiation of transcription 
of IL2, nuclear factor for activated T cells (NF-AT) and AP-1, are sensitive to 
the protein synthesis inhibitor anisom ydn in prim ary hum an T cell 
cultures. They also found that the two-exogenous-signal requirem ent for
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IL2 production in vitro was also required for the production of NF-AT and 
AP-1. NF-AT had previously been found to be specific to T cells (Weiss et 
al., 1984; Verweij it al., 1990).
Other factors which bind to the IL2 promoter-enhancer and are
required for expression: nuclear factor kappa B (NF-kB), octomer binding 
protein 1 (OCT-1) and AP-3. They are constitutively produced and are 
known to be involved in induction of other genes.
The cascade which leads to activation of T cells activates protein 
kinase C, which can act on AP-1. This protein is a complex of various 
members of the Fos and Jun DNA-binding protein families (Sassone-Corsi et 
al., 1988; Jain et al., 1992a: Jain et al., 1992b). Two binding sites for AP-1 have 
been identified in the IL2 promoter-enhancer. The proximal site a t -159 
through -151 (relative to the start of transcription) has been show n to have a 
major effect on IL2 expression although mutational analysis dem onstrated 
that the distal site (-180) also plays a role (Jain et al., 1992a).
The binding sites for OCT-1, AP-1, AP-3, NF-kB, and NF-AT have 
been identified and localized in the sequenced mouse and hum an IL2 5' 
regions (Novak et al., 1990a; Novak et al., 1990b). This confirmed and 
refined findings by Fujita et al. (1986) who used deletion m utations of IL2 
prom oter-enhancer linked to chloramphenicol acetyltransferase (CAT) to 
localize critical cis-acting regions in culture cell extracts. All are located 
within 500 bp of the start of transcription, a region 85% conserved between 
mouse and hum an genomes (Fuse et al., 1984). In addition, Novak et al.
(1990b) also identified c/s-acting regions farther upstream. There they 
located a negative regulatory region between -1219 and -578 and a positive 
regulatory region between -1890 and -1219 bp from the start of transcription 
although their mechanisms of action have not been elucidated.
The closely studied portion of the 5' region from -600 to +43 has been 
used successfully by several groups to control reporter genes in cross species 
in vitro expression experiments (Fujita et al., 1986; Emilie et al., 1989; Novak 
et al., 1990a). There is a convenient PstI restriction endonuclease recognition 
site at +40 (8 bp upstream of the start of translation) in the mouse gene that 
was commonly used to link reporters to the IL2 promoter-enhancer.
Previous research with the IL2 promoter-enhancer was not concerned 
with secretion. However, it was the goal of my research to use the 5' region 
carrying the known specified control sites for mouse IL2 to target expression 
and secretion of the antimicrobial peptide at the location of T cell activation. 
The first 20 amino acids (aa) translated serve as a signal peptide for secretion 
of IL2. The aa sequence is highly conserved among species as diverse as the 
hum an, mouse, cow, and sheep (Figure 1; Fujita et al., 1983; Kashima et al., 
1985; Cerrette et al., 1986; Goodall et al., 1990; Seow et al., 1990). Comparing 
the hum an and the mouse aa sequence, there was 63% homology overall 
including the signal peptide (Kashima et al., 1985) but when side chain 
polarity of unlike aa are considered, signal peptide homology increases to
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M ouse: M Y S M Q  L A S C V T L T L V L L V N S
Human: M Y R M Q  L L S C  I A L S L A L V T N S
C a t t l e :  m y k i q  l l s c i a l t l a l v a n g
s h e e p :  M Y K I Q  L/ p L S C I A L T L A L V A N G
Figure 1. Comparison of IL2 signal sequence among four mammalian 
species. There are two different residues reported for #6 aa in sheep 
(Goodall et al., 1990; Seow et al., 1990).
80%. The same is true of a comparison between mouse and cattle, mouse 
and sheep, hum an and cattle, and human and sheep. Up to 100% homology 
exists between cattle and sheep with a possible single mismatch at aa #6 
(Goodall et al., 1990; Seow et al., 1990).
There is the possibility, then, of using the mouse IL2 promoter- 
enhancer from -595 and signal sequence across species for production and 
secretion of proteins at the site of detection of foreign antigen.
Investigation by Novak et al. (1990b) indicated that there are no 
critical c/s-acting transcriptional control elements in either the introns or the 
3' flanking region as far down stream from the end of the transcript as 5 kb. 
Also, the tight control of expression of IL2 involves not only regulation of 
transcription and alteration of transcription-initiating factors but 
m odulation of the half life of IL2 mRNA. The IL2 3' flanking sequence 
contains an AU-rich motif, which confers sensitivity to degradation by 
ribonuclease (Malter, 1989; Troutt and Kelso, 1992). For these reasons, it was 
not necessary or advantageous to include sequences 3' to the signal peptide 
in an IL2 driven transgene for targeted expression.
LYTIC PEPTIDES 
Lytic peptides are a group of small cationic peptides capable of 
interaction w ith lipid bilayer membranes causing osmotic d isruption and 
cell death (Dawson et al., 1978; Kanellis et al., 1980; Epand et al., 1987; 
Lambert et al., 1989; Hirigoyenberry et al., 1990; Rana et al., 1990; W ade et al., 
1990). Bacterial, protozoan, fungal, and eukaryotic cells w ith com prom ised 
cytoskeletons or altered membranes are most susceptible to d isruption 
(Jaynes et al., 1989; Moore et al., 1994). In various forms they have been 
identified in a wide range of animals from insects to m am m als and, in 
m any cases, are linked to immunodefense systems. Researchers in the field 
generally divide the group into four classes: defensins, m elittins, m againins, 
and cecropins (although, nom enclature is not standardized and other small 
lytic peptides that do not fit into these classes continue to be discovered).
Defensins, 33 to 99 aa, differ from the other three in that they are 
predicted to have a globular secondary structure stabilized by three 
intram olecular disulfide bonds as opposed to an a-helical secondary
structure and the complete absence of cysteine residues in the other classes 
(Selsted et al., 1983; Lambert et al., 1990). Originally discovered in rabbit lung 
m acrophages and eosinophils, defensins have also been isolated from  the 
hem olym ph of im m unized larvae of the D ipteran, Phormia terranovae.
M elittins, magainins, and cecropins have a common m oiety in an 
am phipathic a-helix of at least 13 aa carrying a high positive charge density 
w hen in solution w ith water and low concentrations (8 to 20%, v /v )  of a co­
solvent such as trifluoroacetic acid or l,l,l,3,3,3-hexafluoro-2-propanol 
w hich stabilizes intramolecular hydrogen bonds (Marion et al., 1988; Sipos et 
al., 1992). The helix is configured so that one face is covered by residues w ith 
hydrophobic side chains while the other face is rich in charged and 
hydrophilic side chains, m ost commonly lysine and arginine. The three 
differ in their length, location of a-helix w ithin the molecule, and  presence
of a predom inantly hydrophobic region. Representatives of each class have 
been found to have antimicrobial activity in both the naturally  occurring L- 
isom er and the synthetic D-isomer forms (Wade et al., 1990).
A polipoproteins share w ith the melittins, magainins and cecropins the 
am phipathic a-helical configuration and m em brane associating 
characteristic but not the lytic property (Segrest et al., 1983; Srinivas et al., 
1990).
M elittins, the first of the group to be discovered and investigated, are 
a major com ponent of bee venom comprising 50% of the d ry  weight.
M elittin from  Apis mellifera, the honey bee, consists of 26 aa and two
proposed a-helical regions (Dawson et al., 1978). The am phipathic helix is 
located in the carboxyl-terminal half w ith a run  of six hydrophobic aa on the 
N -term inal required for lytic activity (Habermann, 1972; Dawson et al., 1978). 
M elittin and synthetic analogs which retained the m elittin charge
distribution have been found to be strongly hemolytic at 2 to 100 pM  in vitro 
(Clague and Cherry, 1988; W ade et al., 1990; Arrowood et al., 1991a).
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Appreciable antimicrobial activity occurs in the 0.1 to 3 pM range depending 
upon  the organism and exact compound. These results indicate a factor of 
ten m argin of safety between antimicrobial activity and  cyotoxicity. 
Contrarily, Boman and Steiner (1981) reported that m elittin w as equally 
toxic to bacteria and Chang liver cells .
Perhaps building on the work reported by Gibson et al. (1986) and 
Giovannini et al. (1987), magainins were discovered in and isolated from the 
skin of Xetiopus laevis, the African clawed frog, by Zasloff (1987) after he 
noted that non-sterile surgery and post-operative care resulted in only 
extremely rare instances of infection or abnorm al healing. H e and his 
colleagues proceeded to characterize two 23 aa peptides w ith antimicrobial 
activity against 11 bacteria and fungi in concentrations ranging from 5 to 100 
p g /m l (2 to 40 pM) yet no detectable hemolytic activity w ith concentrations
up  to 150 p g /m l (60 pM; Zasloff, 1987; Rana et al., 1990). The m againins were 
found to be toxic to in vitro grown mouse embryos in concentrations 
ranging from 4 pM for one-cell embryos to 40 pM for blastocysts (Schneider 
et al., 1988). Using nuclear magnetic resonance spectroscopy, M arion et al. 
(1988) determ ined that magainin 2 forms an am phipathic a-helix from Gly-3 
to Asn-22 (accounting for nearly its entire length) w hen in solution w ith 
w ater and  2.3% m olar ratio of trifluoroethanol. W ater alone as solvent 
yielded only random  coils. The three amino-terminal residues are 
hydrophobic; two of them are apparently outside of the helix.
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N aturally occurring members of the cecropin class were first isolated 
from  the hem olym ph of diapause Hylophora cecropia pupae, w hich had 
been im m unized w ith a m oderate dose of live bacteria (H ultm ark et al., 
1980). Cecrpoins have since been discovered in other Lepidopterans (Boman 
and Steiner, 1981; Shiba et al., 1988; Morishima et al., 1990), D ipterans (Okada 
and Natori, 1983; Engstrom et al., 1993; Rosetto et al., 1993) and mammals 
(Lee et al., 1989). In size, the naturally occurring cecropins range from  33 to 
40 aa w ith the first 18 aa forming the am phipathic a-helix and the carboxyl- 
term inal half containing long stretches of hydrophobic aa that form  a second 
a-helix  (Andreu et al., 1985; Boman et al., 1985; Boman and H ultm ark, 1987).
Lytic activity against a w ide variety of free living bacteria has been 
determ ined to be in the range of 0.005 to 7 (xM (Boman and Steiner, 1981; 
A ndreu et al., 1983; Andreu et al., 1985; van Hofsten et al., 1985; Kelly et al., 
1990; Morishima et al., 1990; Shiba et al., 1990; W ade et al., 1990). Effective 
level differs w ith organism and specific peptide w ith no one peptide being 
better at killing all tested organisms. Notable resistance to cecropins by 
Staphylococcus aureus (Morishima et al., 1990; Shiba et al., 1990; W ade et al.,
1990) and Cryptosporidium parvum sporozoites (Arrowood et al., 1991a; 
A rrow ood et al., 1991b) has been documented. The protozoan pathogens 
Plasmodium falciparum  and Trypanosoma cruzi w ere also susceptible bu t 
required a 10-fold higher concentration than susceptible bacteria (Jaynes et 
al., 1988).
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Toxicity to norm al m am m alian cells is low. Bowman and  Steiner 
(1981) reported that Chang liver cells were not lysed by a concentration of 
cecropin A or B 300 times that needed to kill bacteria. Jaynes et al. (1988) 
reported that uninfected Vero cells were unaffected by repeated treatm ent
w ith  levels of cecropins effective against T. cruzi and P. falciparum (40 pM), 
although cells infected with these pathogens were lysed. Reed et al. (1992) 
reported that m ouse embryos from the one-cell stage to the blastocyst stage 
were unharm ed by culture in 10 |iM  of a synthetic cecropin B analog, SB-37, 
in W hitten 's m edium . SB-37 and other synthetic cecropin analogs were 
toxic to 3T3 cells and  primary lymphocytes at 100 pM (Jaynes et al., 1989a; 
Reed et al., 1992). The synthesized L- and D-isomers of cecropin A are non­
toxic to sheep erythrocytes when applied in excess of 200 and 300 pM,
respectively (Wade et al., 1990).
Extensive deletion analysis of the cecropin-class peptide lepidopteran 
A revealed segments critical to lytic activity in 12 different bacterial species 
and  strains (Shiba et al., 1988). Lepidopteran A variants missing at least the 
first six aa were inactive as were those consisting of up  to 12 of the amino- 
term inal residues. In fact, deletion of Arg-1 alone resulted in a dram atic loss 
of lytic activity. A variant consisting of the first 18 aa (Lep 1-18) had  slight 
activity against three bacteria while addition of five more residues m arkedly 
increased activity against nearly all susceptible species. Deletion of as few as 
five residues from the carboxyl-terminal m easurably reduced lepidopteran A
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activity. In a unique experiment, Shiba and associates linked Lep 1-18 via an 
am ide bond at the carboxyl-terminus to aliphatic hydrocarbon chains of 
various lengths. They found that the dodecylamide variant was nearly as 
active as native lepidopteran A underscoring the im portance of charge 
distribution as opposed to aa sequence for lytic activity.
Shiba's group was not the first to synthesize a cecropin. A ndreu et al. 
(1983) and Andreu et al. (1985) earlier reported preparation of cecropin A, a 
37 aa peptide, and deletion and substitution variants used in investigation of 
critical segments. Removal of the amino-term inus dipeptide, Lys-Trp, (Cep 
3-37) severely reduced antimicrobial lytic activity to less than 13% w hile a 
deletion variant m issing the carboxyl-terminus tetra-peptide, Gln-Ile-Ala- 
Lys, (Cep 1-33) retained at least 80% activity when compared to synthesized 
cecropin A. Although deletion of Arg-1 did reduce activity som ewhat, this 
variant was more active than Cep 1-33. Carrying the research further, they 
prepared substitution variants aimed at disrupting the critical amino- 
terminal region. Substitution of Trp-2 w ith a non-aromatic bu t a-helix
form ing residue like glutamic acid resulted in a level of lytic activity lower 
than Cep 3-37. In comparison, a variant w ith phenylalanine, another 
aromatic, substituted for Trp-2 had essentially no loss in activity and they 
hypothesized that the aromatic group was the critical moiety. Rodriguez et 
al. (1995) confirmed that hypothesis. They substituted Trp-2 in a cecropin B- 
like peptide, Shiva 1, w ith Tyr and found no difference in activity.
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Trp-2, highly conserved in natural cecropins, was deem ed critical for 
activity by A ndeu et al. (1985), however, other substitutions that d isrupted
the am phipathic a-helix also caused a loss in activity against m any b u t not 
all m icroorganisms. They sum m arized their results by concluding that 
different portions of the molecule m ay be critical for activity against 
different organisms and that the full length m ay need to be retained for the 
broadest activity. To retain lytic activity, cecropins m ust have at least 1) a 
basic aa followed by an aromatic helix-inducing aa, 2) im m ediately following 
the aromatic, an am phipathic a-helix of at least 15 aa w ith a charged face 
dom inated by basic residues, and 3) a carboxyl-tail of predom inantly 
hydrophobic a-helix-forming residues from 5 to 17 aa long.
Jaynes and colleagues have responded by systematically designing 
cecropin B analogs and testing them for lytic activity and toxicity w ith  the 
goal of developing corresponding genes for plants that either enhance their 
disease resistance (Jaynes et al., 1987,1989a, 1993; Destefano-Beltran et al.,
1991) or utilize them  as bioreactors for synthesizing large quantities of 
peptide inexpensively (Jaynes et al., 1988). The first successful attem pts were 
peptides nam ed SB-37, SB-37*, and Shiva 1 (Jaynes et al., 1988; Jaynes et al., 
1989b). SB-37 has high aa sequence homology w ith cecropin B. A single aa 
substitution of Val for Met at the eleventh position and addition of a Met- 
Pro dipeptide at the amino-terminus altered cecropin B to allow 
developm ent of a cyanogenbromide- cleavable repeat peptide gene product 
(Jaynes et al., 1988). Substituting Val-11 for Met-11 also m ay have served to
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stabilize the a-helix since Val has been shown to be a stronger helix form er
(O 'Neil and DeGrado, 1990). SB-37* has the same changes from cecropin B as 
SB-37 w ith the additional changes of a lysine to leucine substitution a t the 
sixth position and a tryptophan to glutam ate substitution at the second 
position. Recall that for cecropin A, Andreu et al (1985) show ed that Trp-2 
to Glu-2 essentially deactivated the peptide. They also dem onstrated that a 
change of Lys-6 to Leu-6 destroyed activity against Pseudomonas aeruginosa 
bu t had  no effect on activity against Escherichia coli. SB-37*, then, was 
designed to use as a negative control in toxicity and antimicrobial 
experiments. SB-37 retained the same level of antimicrobial activity as 
cecropin B (Nordeen et al., 1992; Jaynes, unpublished data).
Shiva 1 represented a m ore radical departure from cecropin B. 
Approxim ately 60% of the aa residues are different (Figure 2). However, the 
charge distribution, helix-forming tendencies, am phipathic am ino-half and 
hydrophobic carboxyl-half of cecropin B were retained. Again, the Met-Pro 
dipeptide w as added to the amino-terminus and internal Met residues were 
avoided. It was designed specifically "to test whether or not the lytic 
properties of cecropin-like peptides are highly sequence-dependent" (Jaynes 
et al., 1988).
Synthesized Shiva 1 was tested in various experiments for toxicity 
and antim icrobial activity with SB-37*, SB-37, melittin, and a m elittin 
analog, Hecate 1 (Jaynes et al., 1988,1989,1993; White et al., 1989; Kelly et al., 












































































































































Figure 2. Com parison of the DNA code and aa sequence of m ature cecropin 
B (van Hofsten et al., 1985) and Shiva-1 (Jaynes et al., 1988). Hom ologous 
residues are aligned for easier comparison.
found to have broad spectrum  antimicrobial activity on the average equal to 
SB-37. As is common w ith all cecropin variants relative sensitivity was 
unpredictable. Some tested organisms were more sensitive to Shiva 1 than 
SB-37 and some were less. Melittin and Hecate 1 were bacteriacidal a t lower 
concentrations than Shiva 1. Shiva 1 has been reported to be slightly m ore 
toxic to eukaryotic cells than SB-37 but m uch less toxic than either m elittin 
or Hecate 1.
Evaluations of lytic activity against eight im portant fish pathogens 
dem onstrated that Shiva 1 was effective at between 5 nM and 1 |iM  (Kelly et
17
al., 1990). AgainstT. cruzi trypomastigotes, the free living form  of the 
protozoan parasite causing Chagas' disease, effective concentration w as 25
pM. It was also found to be effective in killing T. cruzi infected Vero cells at 
100 pM while leaving uninfected control Vero cells unharm ed. Jaynes et al.
(1988) postulated that the intracellular parasite d isrupted  the cell m em brane 
m aking infected cells more sensitive to lysis.
Jaynes et al. (1989b) hypothesized that transform ed m am m alian cells 
m ay be sensitive to lysis by lytic peptides therefore, Shiva 1, SB-37, SB-37*, 
and  m elittin were tested for cytotoxicity on EL-4 m ouse thym om a, SP2 
m yelom a, U937, and Daudi-Burkitt's lym phom a transform ed cell lines; 
norm al hum an prim ary lymphocytes; and donkey derm al cells (an 
untransform ed fibroblast cell line). Com pared to norm al hum an 
lymphocytes and donkey derm al cells, transform ed lines d id  prove to be 
m ore sensitive to lysis w hen exposed to 100 pM SB-37 for 60 m inutes (min) 
w ith viability reduced 35 to 90% depending upon the line. M elittin d id  not 
differentiate between transform ed and normal cells being highly toxic to all 
cell lines tested. Also, it was found that treatm ent of donkey derm al cells 
w ith either 5 m g /m l cytocalasin D or 10 pM colchicine, both cytoskeletal
inhibitors, greatly increased their sensitivity to 100 pM Shiva 1 or SB-37.
Moore et al. (1994) also reported testing cecropin B, cecropin PI (from 
pig intestine), and Shiva 1 on various cell lines in vitro and finding two cell 
lines w ith the m ultidrug-resistant phenotype to be sensitive to the peptides.
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Also, mice carrying murine ascetic colon adenocarcinoma cells had  
increased survival time w hen treated w ith cecropin B.
There is one report available docum enting the expression of a Shiva 1 
gene conferring disease resistance. Jaynes et al. (1993) described transferring 
a gene for Shiva 1 controlled by a potato proteinase inhibitor II (Pill) 
prom oter via Agrobacterium Ti-plasmid-m ediated gene transfer into 
tobacco plants. The prom oter is induced by w ounding (either mechanically 
or by a pathogen) in the w ounded leaf and in other undam aged leaves, 
stems, and  roots. Expression is undetectable in unharm ed transgenic tobacco 
plants m aking it an ideal prom oter for delivery of an antimicrobial peptide 
(Sanchez-Serrano et al., 1987). Transgenic plants were challenged w ith 
Pseudomonas solanacearum, a vascular tissue pathogen that upon  infection 
causes severe wilting and which was found to be susceptible to killing in 
vitro by 40 fiM of Shiva 1. Tobacco lines testing positive for Shiva 1 
expression by northern and western analysis exhibited delayed appearance of 
sym ptom s of infection that were ultim ately less severe than those on 
control plants. By week four, 55% of the control plants had died while no 
Shiva 1 plants had succumbed to the disease. However, plants expressing 
either SB-37 (Jaynes et al., 1993) or cecropin B (Florack et al., 1995) under the 
control of a constitutive promoter, 35S cauliflower mosaic virus 5' region, 
w ere not resistant to P. solanacearum.
Shiva 1 was chosen as the peptide to be expressed in the transgenic 
mice in these experiments because it has broad antimicrobial activity, it is
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relatively non-toxic to norm al lymphocytes and fibroblasts, and  it has been 
show n to be effective in enhancing disease resistance w hen expressed as a 
transgene.
MATERIALS AND METHODS
CONSTRUCTION OF THE VECTOR 
C loning Of Mouse Interleukin 2 Prom oter/Enhancer
A portion of the mouse IL2 gene from -593 to +110 containing the 
know n prom oter and enhancer regions as well as the portion of open 
reading frame coding for the protein signal sequence was am plified from 
m ouse genomic DNA using polymerase chain reaction (PCR; Saiki et al.,
1988). Template DNA was extracted from 3T3-Swiss Albino fibroblasts 
(ATCC #CCL92) using the m ethod of Higuchi (1989). Briefly, suspended cells 
were added to 200 pi of 50 mM KC1,10 mM tris(hydroxymethyl)amino-
m ethane (Tris)-HCl pH  8.3, 2.5 mM MgCl2, 0.1 m g /m l gelatin (Sigma G- 
2500), 0.45% Tween 20 (Mallinkrodt) and 0.45% Triton X-100 (M allinkrodt)
and frozen at -20°C until used. The sequence of prim ers was determ ined by 
study of the m ouse genomic IL2 sequence published by Fuse it al. (1984) for 
the dow nstream  prim er in the signal peptide coding region and N ovak et al. 
(1990) for the upstream  prim er in the enhancer. The enhancer b u t not the 
coding region was also available as EMBL accession num ber X52618, which 
eased exploration of the sequence. Also, the prim ers were designed so that 
the resulting PCR fragment contained a Sail site at the 5' end and a Bglll site 
at the 3' end to facilitate subcloning. Prim er sequences were S'-TAGAT- 
CTTGC-GCTGT-TGACA-AGGAG-3' for the dow nstream  prim er (IL2-1) and 
5'-AGTCG-ACAAC-GACAA-AATAG-TACCT-3' for the upstream  prim er 
(IL2-2). (See Figure 3 for a listing of primers used in this study and their
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expected product lengths.) PCR conditions were 1.5 mM MgCl2/10 mM Tris- 
HC1, 200 nM each primer, 2 jxM each deoxynucleotide triphosphate (dNTP; 
Perkin-Elmer), 50 mM KC1, 0.01% (w /v) gelatin, 500 ng of m ouse genomic 
DNA and 2.5 units AmpliTaq DNA polymerase (Perkin-Elmer) in  a reaction 
volum e of 100 pi. A Perkin-Elmer Cetus DNA Thermal Cycler was
program m ed with a 3 m in 95°C initial denaturation step; 30 cycles of 1 min
at 95°C, 1 m in at 58°C, and 1 m in at 74°C; and a final elongation step of 7 min
at 72°C. The samples were then held at 4°C until evaluated.
The resultant 715 bp DNA contained the major up  regulatory cis- 
acting sequences of the 5' flanking region, the TATA box, the PstI site at +43,
IL2-1: TAGAT CTTGC GCTGT TGACA AGGAG antisense
IL2-2: AGTCG ACAAC GACAA AATAG TACCT sense
IL2TRANC: CACCC TTGCT AATCA CTCCT sense
MH3UP: CCTGA GCGCT CTCGA ACCGC sense
MH3DN: TTCCG GGGGA TGGTG GTGT antisense
SHIVAlUP: AACCA ACTGC GCGGG CGTCG sense
SHIVAlDN: AGATC TACCA TGCCG CGCTG antisense
IL2-2/IL2-1: 715 bp; amplified IL2 prom oter for cloning. 
IL2TRANC/SHIVA1DN: 235 bp; amplified from the IL2 start of transcription 
to the last codon of Shiva 1 in the recom binant transgene and used for 
detection of IL2-Shiva 1 mRNA and DNA screening. 
SHIVA1UP/SHIVA1DN: 125 bp; amplified Shiva 1 open reading frame and 
used to screen for the presence of the transgene in founder mice. 
M H3UP/M H3DN: 283 bp; amplifies a fragment of m ouse homeobox 3
(Rubin et al., 1986) and used as a positive control in DNA screening. 
IL2-2/SHIVA1DN: 840 bp; amplifies fusion gene IL2 prom oter/enhancer 
plus Shiva 1
Figure 3. Sequences of PCR prim ers used in this study; the pairings, region 
amplified, and the predicted length of the products are shown. Sequence is 
5' to 3'.
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and  the 21 aa signal peptide from mouse IL2, and new  restriction sites a t the 
5' and 3' ends.
A lthough this scheme introduces code for an  intervening series of 
four aa (alanine-arginine-serine-threonine) betw een the signal pep tide  and 
Shiva 1, due to the hydrophilic nature of these residues it was predicted that 
the change w ould not effect activity substantially. N one of these residues 
are specifically a-helix destabilizers. Helix-forming tendency for alanine and 
arginine are high while that of serine is m oderate. H ow ever, threonine 
coupled to methionine-proline, the first two aa residues of Shiva 1 w ould 
likely preclude extension of the am phipathic a-helix to the am ino-term inus 
(O 'Niel and  DeGrado, 1990). Nevertheless, prediction of secondary structure 
in a highly polar context, such as this is, w ould be difficult at the current 
level of knowledge (Lyu et al., 1990), especially considering that the 
hydrophobic micro-environm ent at the m em brane interface plays a role in
form ation of the am phipathic a-helix of cationic m em brane associating 
peptides (Marion et al., 1988; Sipos et al., 1992).
The PCR product was purified and m ade blunt ended using the 
double GeneClean protocol and reagents provided in the GeneClean® II kit 
(BiolOl). Briefly, 300 |xl of N al was combined w ith the 100 |xl reaction and 15
(xl of Glass Milk® (silicate spheres in aqueous suspension that have a strong 
affinity for double stranded DNA >50 bp long) and held on ice for 10 m in 
w ith  occasional gentle mixing. The suspension was centrifuged to pellet the
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beads and the pellet washed three times w ith N ew  Wash® solution. The 
DNA was eluted from the beads w ith 20 pi H20  and a 10 m in 55°C
incubation. A second elution was also perform ed using 50 jxl of H aO.
Clark (1988) has shown that Taq DNA polymerase along w ith Klenow 
enzym e, DNA polymerase I from Saccharomyces cerevisiae, and  others m ay 
add bases to the 3' end of double stranded DNA independent of tem plate 
which inhibits blunt end cloning of these fragments. Also, the prim ers used 
in this PCR reaction did not contain a 5' triphosphate group. Therefore, to
get m axim um  cloning efficiency 25 pi of the elute, 7 pi from the first and 18 
pi from the second elution, were used in a reaction designed to b lunt end
and phosphorylate the PCR product. Ten units (U) of polynucleotide kinase 
(Promega) and 10 U of Klenow enzyme (Promega) were added  to the elute in 
a buffer composed of 50 mM Tris-HCl pH  7.6,10 mM MgCl2, 1 mM 
dithiothreitol (DTT), 10 mM adenosine triphosphate (ATP), 20 nM  each
dNTP, and  50 p g /m l high purity  bovine serum  album in fraction 5 (BSA; 
Miles Laboratories) in a total volume of 100 pi and incubated at 37°C for 1 h. 
After addition of 1 pi of 0.5 M ethylenediaminetetraacetic acid (EDTA) to 
stop the reaction, the DNA was rem oved from the solution using a second 
GenClean procedure similar to the first. A single elution step in 25 pi of 
H 20  was used to re-suspend the DNA.
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The PCR product was then cloned into the Smal site of pUC18 
(Messing, 1983; United States Biochemical; Figure 4). A m olar ratio of 
approxim ately three parts pUC18 to four parts IL2 enhancer/prom oter (a 3:1 
m ass ratio) was used in a ligation reaction containing 150 ng pUC18 Smal 
digest, 50 ng  IL2 DNA, 20 mM Tris-HCl pH 7.6 ,5 mM MgCl2, 5 mM DTT, and
50 (ig /m l BSA (Sambrook et al., 1989). Ligation was perform ed overnight at 
16°C.
Transform ation of E. coli strain DHSaMCR (Life Technologies) was 
perform ed w ith frozen competent cells prepared and utilized exactly as 
described by Sambrook et al. (1989). This strain has a nonfunctional /3- 
galactosidase (p-gal) bu t allows a-com plem entation for a return  of function
(Ullmann et al., 1967). The plasmid pUC18 contains lacZ' under control of 
the lac prom oter (lacl) which can be induced by isopropyl-thiogalactoside 
(IPTG). Insertion of a foreign fragment in the Smal site uncouples lacZ'
from the prom oter preventing (3-gal function. This allows screening of 
clones containing an insert by exposing colonies to the (3-gal substrate 5- 
bromo-4-chloro-3-indolyl-[3-D-galactopyranoside (Xgal), which turns blue 
upon cleavage by [3-gal. Colonies containing plasm id w ith no insert are blue
w hereas those containing plasmid with insert are white.
One hundred nanograms of ligated DNA was used for the 
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Figure 4. Construction of pILSHIX/neo and source of IL2/Shiva 1 gene 
for pronuclear injection of mouse pronuclear stage embryos. Plasm ids and 
fragm ents are to scale in Figures 3 and 4. pUC18 was purchased from US 
Biochemical, pMClneoPolyA from Stratagene, and pShiva-1 was as 
described by Jaynes et al. (1993).
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al., 1989) culture plates containing 100 p g /m l ampicillin and spread w ith 40 
|xl of 2% Xgal and 0.1 M IPTG as described in Sambrook et al. (1989) were
used to culture 200 pi of the cell suspension. Approxim ately 40% of the 
colonies were white. Eight white colonies were grown over night in Luria- 
Bertani M edium  (LB; Sambrook, 1989) and alkaline lysis m inipreparations 
perform ed (Birnboim and Doly, 1979). Isolated plasm id was digested with 
H ind lll (Promega) and those clones which appeared to contain the correct 
size DNA were digested with Bglll (Pharmacia).
A single clone which cut w ith Bglll was further investigated w ith 
restriction endonuclease digest. The mouse IL2 prom oter/enhancer 
contains a convenient PstI site 43 bp inside the open reading frame. This site 
has been used in transient expression studies of prom oter function by 
N ovak et al. (1990) and Emilie et al. (1989). It was used here to check the 
integrity and orientation of the recombinant DNA. In addition, Bglll/EcoRI 
(Life Technologies), Sail, and Bglll/PstI digests were performed.
Incorporation, restriction site integrity, and orientation were consistent. The 
resulting plasm id was nam ed "pUCIL".
Integration of Shiva 1 w ith IL2
The Shiva 1 gene had been synthesized and cloned into the plant 
plasm id vector pMON530 by Jaynes and others in the D epartm ent of 
Biochemistry, Louisiana State University (Jaynes et al., 1993; Destefano- 
Beltran et al., 1991). The Shiva 1 fragment was digested from the plasmid, 
separated by agarose gel electrophoresis (40 mM Tris-acetate, 1 mM EDTA
(TAE) buffer), and eluded by the procedure described by Zhu et al. (1985). 
Plasmid pUCIL was digested with Bglll and EcoRI and purified w ith the 
GeneClean II procedure. The glass beads of the GeneClean kit bind DNA 
fragm ents smaller than 50 bp poorly allowing removal of unw anted  small 
fragm ents from a solution. The unw anted Bglll-EcoRI fragm ent of pUCIL is 
only 16 bp, so subjecting this solution to GeneClean reduced the 
recom bination of the vector in the subsequent ligation. Shiva 1 fragm ent 
(128 bp) and vector (3385 bp) were combined in a ligation reaction at a 2.25:1
m olar ratio using 30 ng of pUCIL, 2.5 ng of Shiva 1,10 Mg/ml BSA (Sigma), 1
Weiss unit of T4 ligase (Promega), and Promega Ligase Buffer in a 10 |il
reaction. DHSocMCR were transformed as described above using one half of 
the ligation reaction. Colonies were screened as above using PstI and EcoRI 
digests and one clone was chosen to use in further experim entation 
(pILSHI).
Sequencing IL2-Shiva 1 Gene
There was a concern that replication using Thermus aquaticus (Taq) 
DNA polymerase which has no 3' to 5' exonuclease proofreading activity 
w ould cause substitution mutations that could interfere w ith the proper 
function of the IL2 region (Tindall and Kunkel, 1988). Also, although a 
clone of Shiva 1 which had been inserted into pUC19 had been sequenced 
and found to agree w ith the sequence program m ed into the DNA 
synthesizer (data not shown), that clone was two subclones rem oved from 
pILSHI. In addition, the correct sequence at the interface of the IL2 signal
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w ith  Shiva 1 was critical for correct in frame translation. Therefore, a 
definitive determ ination of the sequence of the IL2-Shiva 1 gene was m ade 
by DNA sequencing using the dideoxynucleotide m ethod pioneered by 
Sanger et al. (1977) but m odified to accommodate double stranded tem plate 
(Sambrook et al., 1989; United States Biochemical, 1990). Sequencing was 
perform ed from both ends using the M l3 Universal and Reverse prim ers 
(US Biochemical) as well as the IL2-1 prim er (Figure 3) for better resolution 
of the m iddle of the construct. A set of reactions using inosine in  place of 
guanosine were included to reduce band compression in  regions of strong 
in trastrand secondary structure (United States Biochemical, 1990).
Plasmid DNA previously isolated by m iniprep w as further purified by 
treatm ent w ith phenol pH  8.0, phenol:chloroform:isoamyl alcohol (25:24:1), 
and  three treatm ents of chloroform. It was then precipitated w ith ethanol 
using sodium  acetate as the m onovalent cation source, resuspended in TE 
buffer pH  7.6 (10 mM Tris-HCl pH  7.6,1 mM EDTA pH  8.0; Sambrook et al., 
1989), and  quantitated by m easuring absorbence at 260 nm. Twenty-five 
nanogram s of pILSHI were treated with 100 mM NaOH at room  tem perature 
for 5 m in then ethanol precipitated using amm onium  acetate, w ashed twice 
w ith 70% ethanol, dried in a vacuum, and resuspended in  w ater purified 
through deionization and reverse osmosis cartridges to a conductivity of at
least 17.5 MO-cm (type 1 water).
Five nanogram s of denatured DNA were transferred into each of 
eight tubes, to make a set of four reactions for each primer. Prim ers were
added, the solution heated to 65°C for 2 min in a heat block then cooled 
slowly by placing the block on the bench at room tem perature until the 
tem perature dropped below 30°C to allow primers to anneal to the template.
The labeling reaction was carried out as described in the Sequenase II Kit 
(United States Biochemical) using a labeling mix diluted 1 to 5 and 
Sequenase T7 DNA polymerase diluted 1 to 8 to allow reading of 30 to 200 
bases from the prim er and in the presence of 6.25 jj.Ci of a 3SSdATP. After 6 
to 7 m in at room  tem perature, term ination mix containing the 
corresponding dideoxynucleotide was added to each and the incubation 
continued for an additional 5 min at 37°C. To reduce artifact bands, a 
m ixture of 1 mM of each dNTP to a final concentration of 0.05 mM  and 8.5 U 
of terminal deoxynudiotidyl transferase was added to each reaction and 
incubation extended 30 min (Fawcett and Bartlett, 1990).
A ddition of the Polyadenvlation Signal and Splice Site
The Simian Virus 40 polyadenylation signal and splice site (SV40 
polyA & splice) were added to help m aintain integrity of the transcript 
during  translation (Figure 5).
Twenty-two micrograms of the superlinker cloning vector pSL1190 
(Pharmacia) was digested with BamHI (Pharmacia) and Sail (Pharmacia) and
1.2 |ng of m am m alian expression vector pMSG was digested w ith BamHI and
Xhol (New England Biolabs) in One-Phor-AU (OPA) buffer (Pharmacia). 
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Figure 5. Construction and isolation of an SV40 polyadenylation signal 
and  splice site with EcoRI site designed to link to the 3' end of Shiva 1. 
Plasmids and fragments are to scale in Figures 4 and 5. pSL1190 and 
pMSG were purchased from Pharmacia Biotechnology.
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of pMSG yielded fragments of 36,848, and 3386 bp and the digest of pSL1190 
yielded fragments of 37 and 3485 bp. This removes the SV40 polyA & splice 
(848 bp) from pMSG and prepares pSL1190 (3485 bp) for receipt of the 
fragm ent.
After deactivation of restriction endonucleases by incubation at 85°C
for 20 m in and  phenol extraction followed by ethanol precipitation, an  equi- 
m olar concentration of the two restriction digests, 250 ng  of pSL1190 and 500
ng  of pMSG were mixed in a 10 jxl ligation reaction using 3 U of T4 ligase 
(Promega) in IX OPA buffer w ith 1 mM ATP. The reaction was incubated 
overnight at 16°C in a heat block surrounded by 4°C am bient tem perature. 
Ligation of Xhol and Sail compatible cohesive ends destroyed the Sail site of 
pSL1190.
Frozen com petent E. coli strain DH5aMCR cells were transform ed
using the m ethod previously described (Sambrook et al., 1988). 
M inipreparations of colonies grown in SOB m edium  (Sambrook et al., 1988) 
containing 100 m g /m l ampicillin were screened using a BamHI/EcoRI 
digest. Religated pMSG yields three fragments: 751, 2250, and 4625; religated 
pS11190 yielded two fragments 58 and 3364 bp; the correct construct, 
pSLl 190/Pol A, yielded two fragments: 908, and 3364 bp.
Two prom ising clones of 20 the screened were digested w ith Xbal 
(New England Biolabs) and Spel (Life Technologies) in IX OPA® buffer and 
checked on an agarose gel. At this point, one clone was discarded when it
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failed to cut with either enzyme. To get a fragm ent bounded by EcoRI and 
Afllll that could be ligated into a pILSHI fragm ent having identical cohesive 
ends (Afllll has m ultiple recognition sequences), two Afllll sites from the 
m ultiple cloning site that has a different m iddle pair of bases in the cohesive 
end had to be removed. The Xbal/Spel fragment contains these Afllll sites 
and the cohesive ends of Xbal and Spel are complementary allowing easy 
religation. The fragment removed was 144 bp and contained a unique PstI 
site. Therefore, to reduce background in the following ligation, the reaction 
products were further digested w ith PstI in IX OPA for lh  at 37°C and chilled
on ice imm ediately before adding 3 Weiss units of T4 ligase and ATP to a 
final concentration of 1 mM.
E. coli was transformed and clones screened as described above using a 
Bglll (Pharmacia)/HindIII(Promega) double digest in Promega buffer B and a 
PstI (Pharmacia) digest. Nine of ten clones were identified as having the
correct deletion; one was selected and nam ed "pSLpolAA".
Plasm ids pSLpolAA and pILSHI were digested with EcoRI (Life
Technologies) and Afllll (New England Biolabs) in REact4 buffer (Life
Technologies). The desired fragm ent from pSLpolAA was 1376 bp as the
insert and that from pILSHI was 3164 bp as the vector. These were gel 
purified using 1% SeaKem GTG® agarose (EMC), TAE electrophoresis 
buffer, and  FMC's Spinbind® columns as directed by the company. The 
isolated fragments were combined in a molar ratio of 2 moles of insert to 1
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mole of vector and an approximate total of 200 ng of DNA. Transform ation 
and screening identified nine of nine colonies tested contained the correct 
plasmid. One was selected and named "pILSHIX".
Insertion of N e o  Cassette
To use the construct to stably transfect m am m alian cells in vitro, a 
selectable marker, a neomycin phosphotransferase (Berg et al., 1975) 
expression cassette was then cloned into the Sail site in pILSHIX upstream  of 
the IL2 prom oter/enhancer and oriented to transcribe in the opposite 
direction from the Shiva 1 cassette. This cassette from pMCIneoPOLA 
consisted oineo under control of the herpes virus thym idine kinase 
prom oter w ith transcript processing using a synthetic polyadenyl-ation 
signal (Thomas and Capecchi, 1987; Stratagene). Plasmid pMCI was digested 
w ith Xhol and Sail in IX OPA® buffer and pILSHIX was digested w ith Sail in 
Sail buffer (New England Biolabs). After testing for completion of reaction, 
both reactions were phenol extracted and ethanol precipitated. They were 
then mixed in a one to one molar ratio and ligated (2 h at 15°C) then used to
transform  E. coli described above. HindHI digest of m inipreps indicted two 
of 24 colonies tested had the correct clone. The resulting plasm id was 
nam ed "pILSHI/neo".
PRODUCTION OF TRANSGENIC MICE
DNA Preparation
A 1713 bp BamHI fragment of pILSHIX containing only !L2fShiva-l 
w as used for the production of transgenic mice. DNA was isolated using
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alkaline lysis and purified by passage through a Spinbind colum n (FMC) and 
eluted in 50 pi microinjection buffer. Microinjection buffer consisted of 10 
m M  Tris pH  7.4, 0.15 mM EDTA in type 1 w ater carefully filtered through a 
0.2 pm  pore-size m ixed esters of cellulose filter (Millipore) in a biosafety 
hood to avoid contamination by dust which could clog the microinjection 
needle. RNase A (Sigma) was added and plasm id digested w ith BamHI in
60 pi volum e of REact 3® (Life Technologies). The fragm ents generated 
w ere 1713 and 2758 bp which were separated on a 1% TAE agarose gel. The 
1713 bp band was excised from the gel and the DNA isolated using the 
Spinbind® system. Microinjection buffer was again used for elution from 
the colum n.
DNA was further purified w ith microdialysis. A 25 pi drop of IL2- 
Shiva 1-SV40 polyA DNA solution was pipetted to the center of a 27 m m  
diam eter, 0.025 pm  pore-size mixed esters of cellulose m em brane (Millipore) 
w hich was floating on 10 ml of microinjection buffer in a 100 m m  
polystyrene petri dish. Dialysis was carried out for 48 h against two changes 
of microinjection buffer during which time the dish was sealed w ith
Parafilm® (American Can). At the end of the period, an additional 10 pi of
microinjection buffer was added to the sam ple spot, pipetted  up  and  dow n to 
m ix and the solution transferred to a microcentrifuge tube. Two microliters 
of the solution w as stained w ith Hoechst 33258 and used to determ ine the 
concentration by spectrofluorometry using a TKO 100 instrum ent (Hoefer)
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and the protocol supplied by the manufacturer. The rem aining solution was 
then diluted to 2 ng /fil final working concentration w ith microinjection 
buffer.
Embryo Production and Pronuclear Injection
Transgenic mice were produced using the standard  protocol used 
routinely by Morrey and his associates w ith the AIDS Research Program  at 
U tah State University (Morrey et al., 1993; Morrey et al., 1992; Morrey et al., 
1991). Briefly, two groups of 20 four-week-old female FVB/N strain mice 
(Taketo et al., 1991; Teconic Farms, NY) were synchronized and 
superovulated w ith pregnant mare serum  gonadotropin (PMSG; Sigma) and 
hum an chorionic gonadotropin (hCG; Sigma). Seven international units 
(IU) of each hormone in 0.1 ml of sterile normal saline w ere given by 
intraperitoneal injection to each mouse. PMSG and hCG were adm inistered 
67 to 68 h and 20 to 21 h, respectively, prior to removal of embryos from  the 
m ouse. M ating was perform ed by proven FVB/N strain males. The 
following m orning, m ated mice were sacrificed by hum ane m eans (cervical 
dislocation or CO2 asphyxiation. The embryos were collected from  the
oviducts, and held in M2 m edium  (Pratt, 1987). Embryos were m aintained
at 37°C before, during, and after manipulation. Under 400x Hoffman optics,
em bryos were microinjected w ith 2 ng /(il DNA solution into the male
a n d /o r  female pronuclei until the nuclear membrane visibly swelled.
W ithin 2 h after injection, embryo transfer surgery was perform ed on
tribrom oethanol (Avertin) anesthetized (Pratt, 1987) Swiss-W ebster strain
females, which had been m ated 12 to 16 h earlier to vasectomized ICR strain
males. Seven-week-old Swiss-Webster females were used as the foster strain
because of their superior m aternal ability. The ICR strain had  been
previously bu t they occasionally cannibalized their litters especially w hen
disturbed w ithin a few days of giving birth; this never happened w ith the
Swiss-Webster foster mothers. Approximately 15 em bryos were transferred
to each oviduct of each recipient using a finely draw n glass pipette.
SCREENING TRANSGENIC MICE AND DETECTION 
OF SHIVA 1 EXPRESSION
Initial screening of possible transgenics was m ade using PCR. After 
individual identification by toe clipping, 1 to 2 cm of tail was cut from  each 
m ouse w ith sharp clean scissors. The tail piece was subjected to overnight 
digestion in 500 pi of tail lysis buffer (100 mM Tris-HCl, 5 mM EDTA, 0.2% 
sodium  dodecyl sulfate (SDS), 200 mM NaCl, 14 p g /m l proteinase K, pH  8.0).
Undigested debris was removed by centrifugation at 20000 x g  and genomic 
DNA was precipitated from the supernatant w ith isopropanol. The pellet
was rinsed in 70% ethanol, dried in air, and resuspended in 200 pi TE pH  7.6. 
The suspension was heated to 65° C for 1 h to deactivate residual proteinase
K and aid  in dissolving the DNA.
Five microliters of this solution were used in PCR along w ith 20 pMol 
each SHIVA1UP and SHIVA1DN primers (Figure 3), 2.5 U Taq DNA 
polym erase (Promega), GeneAmp PCR Buffer (Perkin Elmer), and  0.2 mM
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each dNTP. The reaction was perform ed at 94°C for 3 m in to denature
genomic DNA; 25 cycles of 94°C for 1 min, 58°C for 1 min, and 72°C for 1.5
min; and a final elongation period of 5 m in at 72°C. The reaction products 
were evaluated in gels consisting of 1.5% agarose in 45 mM Tris-borate, 1 
mM  EDTA (0.5X TBE) gels stained with ethidium  bromide.
Southern blot analysis (Southern, 1975) was perform ed on PCR 
positive mice using BamHI and EcoRI/Sail digested tail DNA. Biotin- 
labeled pILSHI served as the probe and the procedure followed the 
instructions included in the Polar Plex® Chem ilum inescent Kit (Millipore). 
Digested DNA was subjected to electrophoresis in 1% 0.5X TBE agarose then 
transferred by pressure blotting (Stratagene) to Immobilon-S® nylon 
m em brane (Millipore). Prehybridization, hybridization, and 
chem ilum inescent detection were carried out as described in the kit.
Some of the mice testing positive for Shiva 7 by PCR were bred to 
norm al FVB/N and Swiss-Webster mice. Ft and F2 generation mice were 
screened for the presence of Shiva 1 DNA by PCR.
A random  sample of the DNA-positive animals along w ith norm al 
FV B/N and Swiss-Webster mice were tested for expression of IL2-Shiva 1 
mRNA in in vitro cultured prim ary lymphocytes. Mice were sacrificed, a 
tail sam ple taken, and spleens removed. Instrum ents were cleaned w ith 
70% ethanol between each mouse. DNA was extracted from the tail sam ple 
as described above. Under sterile conditions spleens were minced in H ank's 
buffered saline solution (HyClone Laboratories) and cell suspensions
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transferred to centrifuge tubes. After pelleting, the cells were resuspended in 
9 ml of sterile type 1 water and held for 20 sec to lyse red blood cells then 1 
ml of sterile 10X phosphate buffered saline (PBS; HyClone Laboratories) was 
added to bring the solution back to isotonic conditions. Large pieces of debris 
were rem oved from the suspension and the rem aining cells pelleted. 
Discarding the supernatant between centrifugations, the cells were w ashed 
twice in Hybri-Care® (American Type Culture Collection) or RPMI-1640 
(HyClone Laboratories) containing 10% fetal bovine serum  (FBS; HyClone 
Laboratories) then resuspended in 2 ml of Hybri-Care® or RPMI-1640 plus 
10% FBS or Lymphocyte Culture Fluid (Torres et al, 1993) and  transferred to 
35 m m  suspension cell culture dishes (Sarstedt). Gentamicin (Life 
Technologies) to 0.1 m g /m l and hum an recom binant IL2 (Sigma or Life 
Technologies) to 10 IU /m l were added to each culture. Cells were grown 
overnight at 37°C, 5% C 0 2 in air then split by volume into two equal 
portions. The total volume of m edium  was returned to 2 ml and 
Gentamicin and IL2 adjusted to the above concentrations. To one of each 
pair of cultures, concanavalin A (ConA) was added to a final concentration 
of 3.25 |xg/ml. After an additional 48 h incubation, cells were counted and 
harvested for RNA extraction. Cleared culture m edium  was frozen at -20°C 
for later Shiva 1 detection.
Total RNA was extracted from 5 x 106 cells using Trizol® RNA 
Extraction Reagent (Life Technologies) using the protocol included w ith the 
product. The m ethod is based on guanidine isothiocyanate extraction
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developed by Chomazynski and Sacchi (1987). Barrier pipette tips, 
diethylpyrocarbonate (DEPC) treated type 1 water, glassware baked overnight
at 180°C, frequent changes of latex gloves, and new, autoclaved
microcentrifuge tubes were used to avoid cross contam ination and 
introduction of ribonucleases (RNase) into the solutions being handled.
RNA yield and concentration was determ ined by absorption 
spectrophotom etry at 260 nm assum ing 1 OD260= 40 p g /m l (Sambrook et al.,
1989).
One m icrogram or 0.6 pg of total RNA was subjected to reverse 
transcription PCR (RT-PCR). The m ethod used selects polyadenylated 
mRNA from a pool of total RNA and converts it to DNA by reverse 
transcription using a 15 base polydeoxythym idylate oligonucleotide prim er 
(oligo15dT) and reverse transcriptase enzyme from avian myeloblastosis 
virus (AMV-RT). A portion of the IL2-Shiva 1 double stranded DNA from 
the transcript was then amplified using PCR and prim ers specific for this 
target. Reverse transcription was conducted in RNase-free w ater w ith 5 mM 
M gCl2, RT Buffer (Promega), 1 mM each dNTP, 25 p i/m l rRNasin®
(Promega), 0.75 U /p l AMV-RT (Promega), and 0.025 n g /p l oligo15dT. Each 
reaction had a total volume of 20 pi and was incubated at 42°C for 15 min. A 
parallel set of reactions to test for the presence of contam inating DNA 
contained all ingredients except AMV-RT.
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The total reverse transcription reaction volume was used in a 100 |il
PCR w ith the addition of 4 |iil of 50 mM MgCl2/ 8 |il RT buffer, 20 pM ol of 
each IL2TRANC and SHIVA1DN primers (Figure 3), 2.5 U Taq DNA 
polym erase (Life Technologies), and 65.5 jxl RNase-free water. Reactions 
were carried out at 94°C for 7 min; 40 cycles for 94°C for 15 sec, 56°C for 30 sec, 
and  72°C for 30 sec; then 72°C for 7 m in Tem perature of the solution was 
dropped  to and held at 4°C until gel electrophoresis.
Tail DNA was tested w ith the IL2TRANC/SHIVA1DN prim er set to 
insure correct identification of transgenic animals and fidelity of the 
reaction. Also, as a positive control of the ability of DNA extracted from 
negative control animals to amplify, a set of prim ers for the m ouse 
hom eobox 3 gene known to be tightly controlled for expression only in 
sperm atocytes during late meiosis and embryos 11.5 to 12.5 d  post coitum 
(Figure 3; Rubin et al., 1986) were used following the above PCR conditions. 
Five m icroliters of the RT-PCR and tail DNA PCR w ere evaluated on a 1.5% 
0.5X TBE agarose gels stained w ith ethidium  bromide.
Supernatants of cell growth medium  were cleared by centrifugation 
(20000 x g) and evaluated for presence of Shiva 1 peptide by do t blot using a 
polyclonal antibody generated against Shiva 1 in rabbits (supplied by F.M. 
Enright, Louisiana State University) and a ELISAmate® Kit system  w ith 
alkaline phosphatase conjugated goat anti-rabbit IgG (Kirkegaard and Perry 
Laboratories). Samples were applied in triplicate. Serial dilutions
containing from 0 to 4 |ig total synthesized Shiva 1 were used as controls. 
TBS buffer (20 mM Tris, 0.5 M NaCl, pH  7.5) was used to prew et 
nitrocellulose m em brane before assembly in the dot blot apparatus (BioRad). 
Each well was washed three times with TBS then 300 pi of supernatant was 
added  and  allowed to flow by gravity through the mem brane. Vacuum was 
applied for 1 h to dry the membrane. Filtered Blocking Solution (Kirkegaard 
and Perry Laboratories) was applied to each well then rinsed twice w ith 
W ash Solution (Kirkegaard and Perry Laboratories). Rabbit anti-Shiva 1 
antibody at a 600:1 dilution in Milk Diluent (Kirkegaard and Perry 
Laboratories) was loaded into each well and incubated covered for 1 h  before 
being draw n through the membrane by vacuum. The m em brane was 
w ashed five times w ith W ash Solution. Goat anti-rabbit antibody 
conjugated to alkaline phosphatase, diluted 600:1 in Milk Diluent, was 
allowed to interact w ith the contents of each well for 1 h. U nbound antibody 
w as then w ashed through the membrane by rinsing five times w ith W ash 
Solution (Kirkegaard and Perry Laboratories). The m em brane was rem oved 
from  the apparatus and exposed to BCIT/NBT® substrate (Kirkegaard and 
Perry Laboratories) for detection of alkaline phosphatase. Detection 




Am ong the reaction sets using the three prim er pairs, the entire IL2- 
Shiva 1 gene sequence was determ ined (Figure 6). To attain a clear readable 
sequence, the dried  gel was exposed to XAR radiographic film (Kodak) for 52 
h. The long exposure time overexposed the M13 single stranded tem plate 
reactions used as the control but it remained readable for over 150 bases.
The cloned sequence of Shiva 1 agrees w ith that originally 
program m ed (Figure 2). Band compression in the sequencing gel in the G 
and C lanes resulted in a possible discrepancy. It appeared that a 
transposition occurred between bases 79 and 80 turning Ala-27 to Arg-27 at
the beginning of the hydrophobic a-helix, which could have had  a major
im pact on activity. The discrepancy was resolved, however, by the lanes 
containing the inosine reactions. Band compression was relieved and the 
sequence was clearly correct.
A single base A to C transition within the code for the IL2 signal 
sequence was discovered w hen compared to the sequence published by Fuse 
et al. (1984). This is the first base in the Leu-12 codon bu t the substitution did 
not effect the aa sequence (UUG to CUG). Also, an investigation of the 
frequency of codons for Leu in m ouse IL2 found that UUG w as as common 
as CUG. Therefore, the change should not adversely effect expression or 
secretion of Shiva 1. All other sequence was identical to that reported by 
Fuse et al. (1984) and Novak et al. (1990b).
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B T — AAAAC QACOO CCAOT
-5 9 9
OCCAA OCTTO CATOC CTOCA OOTCO ACTCT AOAOO ATCCC C a g t c
-5 9 0  -5 8 0  -57 0  -5 6 0  -5 5 0  -5 4 0  -531
g a c a a  c g a c a  a a a t a  g t a c c  tCAAG CTCAA CAAGC ATTTT AGGTG TCCTT AGCTT ACTAT TTCTC
-5 2 0  -5 1 0  -5 0 0  -4 9 0  -4 8 0  -4 7 0
TGGCT AACTG TATGA AGCCA TCTAT CACCC TGTGT GCAAT TAGCT CATTG TGTAG ATAAG AAGGT
-4 6 0  -4 5 0  -4 4 0  -4 3 0  - 4 2 0  - 4 1 0  -4 0 1
AAAAC CATCT TGAAA CAGGA AACCA ATATC CTTCC TGTCT AATCA ACAAA TCTAA AAGAT TTATT
-3 9 0  -3 8 0  -3 7 0  -3 60  -3 5 0  -3 4 0
CTTTT CATCT ATCTC CTCTT GCGTT TGTCC ACCAC AACAG GCTGC TTACA GGTTC AGGAT GGTTT
-3 3 0  -3 2 0  -3 1 0  -3 00  -2 9 0  - 2 8 0  -2 7 1
TGACA AAGAG AACAT TTTCA TGAGT TACTT TTGTG TCTCC ACCCC AAAGA GGAAA ATTTG TTTCA
-2 6 0  -2 50  -2 4 0  -2 3 0  -2 2 0  -2 1 0
TACAG AAGGC GTTCA TTGTA TGAAT TAAAA CTGCC ACCTA AGTGT GGGCT AACCC GACCA AGAGG
-2 0 0  -1 90  -1 8 0  -1 7 0  - 1 6 0  -1 5 0  -14 1
GATTT CACCT AAATC CATTC AGTCA GTGTA TGGGG GTTTA AAGAA ATTCC AGAGA GTCAT CAGAA
-1 3 0  -1 2 0  -1 10  -1 0 0  - 9 0  - 8 0
GAGGA AAAAC AAAGG TAATG CTTTC TGCCA CACAG GTAGA CTCTT TGAAA ATATG TGTAA TATGT
-7 0  -6 0  - 5 0  -4 0  -3 0  -2 0  -11
AAAAC ATCGT GACAC CCCCA TATTA TTTTT CCAGC ATTAA CAGTA TAAAT TGCCT CCCAT GCTGA
-1+1  +10 +20 +30 +40 +50
AGAGC TGCCT ATCAC CCTTG CTAAT CACTC CTCAC AGTGA CCTCA AGTCC TGCAG GCATG TACAG
+60 +70 +80 +90 +100 +110 +119
CATGC AGCTC GCATC CTGTG TCACA CTGAC ACTTG T G C tc  c t t g t  c a a c a  g c g c a  a g a t e  taC C A
+130 +140 +150 +160 +170 +180
TGCCG CGCTG GCGTC TGTTC CGCCG TATCG ACCGT GTTGG CAAAC AGATC AAACA GGGTA TCCTG
+190 +200 +210 +220 +230 +239
CCGTG CTGGC CCGGC TATCG CTCTG GTTGG CGACG CCCGC GCAGT TGGTT GAGAA
T T C O T  A A TCA  TO G TC  A TA QC T Q T T T  CCTOT QTOAA
Figure 6. The sequence of pILSHI from the Universal prim er to the Reverse 
prim er (M13 vectors). Underlined indicate the sequence of the Reverse and 
Universal primers. Sequences were readable within 10 bases of the 
primers. Lower case letters represent PCR prim er sequences used to extract 
m ouse IL2 prom oter/enhancer from genomic DNA. Italics are Shiva 1 
sequence. Bold face type are bases native to pUC18. Origin (+1) is the 
presum ed start of transcription. Translation starts at +48.__________________
44
SCREENING OF FOUNDERS 
Four hundred  and thirty-eight FVB/N embryos in two groups two 
weeks apart were injected w ith the BamHI fragm ent of pILSHIX (Figure 5).
A total of 78 pups, 34 in the first group and 44 in the second, were born in 12 
litters averaging 6.5 pups/litter (range: 4 to 10). PCR screening revealed a 
total of 26 (six from the first group and 20 from the second group) of the 78 
animals (33%) carried Shiva 1 (Table 1; Figure 7). Palmiter and Brinster 
(1986) reported that, typically, mouse embryo pronuclear injection produces 
25% transgenics of the mice born so these results agree favorably w ith 
historical proportions.
Table 1. Success rate of pronuclear injection of two groups of m ouse 
em bryos
No. Embryos No. Transgenic
G roup Injected No. Litters No. Pups (% of those born)
1 200 5 34 6 (18%)
2 238 7 44 20 (45%)
Southern blots of a set of BamHI digests of tail DNA from the 
positive founders were inconclusive (data not shown). Faint positive bands 
were disclosed in eight of the 28 lanes but they were m uch larger fragm ents 
than expected having an approximate size of 5000 bp. A probe of a set of 
EcoRI/Sall digests also revealed a large fragment of approxim ately 5000 bp in 
11 samples. As before, these bands were very faint. The two sets overlapped 
bu t three of the animals found positive in the BamHI set were not positive
I anp  D iscription______________
1 0.28 jig pBR322 Haelll marker
2 FCR reaction #3 DNA
3 PCR reaction #12 DNA
4-12 PCR reaction #22-#30 DNA
13 BLANK
14 0.28 jig pBR322 Haelll marker
15-17 PCR reaction #32-#34 DNA
18 PCR reaction #6 DNA
19 PCR reaction of no template negative control
20 PCR reaction of pILSHIX/neo positive control
21-24 BLANK
Figure 7. Results of PCR amplification of DNA extracted from the tail tis­
sue of potential transgenic mice. PCR utilized primers specific for Shiva 1 
(SHIVA1UP/SHIVA1DN). The positive result was a 125 bp  fragment 
amplified from DNA of m ouse #3 (lane 2), #12 (lane 3), #22 (lane 4), 
#23(lane 5), #27 (lane 9), and #34 (lane 17). A positive control using 
pILSHIX/neo as a template also amplified a 125 bp fragm ent (lane 20). 
No-template negative control was loaded in lane 19 and as expected had 
no amplification of a specific fragment. The gels were 1.5% agaraose 0.5X 
TBE stained after electrophoresis w ith 1 jig /m l solution of ethidium  bro­
mide. Lanes are num bered sequenctially from left to right across the two 
gels. Lanes containing PCR products were loaded w ith 10 pi of the 100 pi 
total reaction volume.
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in the EcoRI/Sall set. Additional exposure time d id  not clarify the results 
due to high background.
EVALUATION OF TRANSGENIC LINES 
Palmiter and Brinster (1987) found that due to delayed integration, 
30% of transgenic mice produced by pronuclear injection are mosaics. Some 
mosaics failed to carry the transgene in their germ cells and others displayed 
some degree of germ cell mosaicism. To test the transgenic lines for ability 
to pass the transgene to offspring, eight founders were bred to norm al 
FV B/N  and Swiss-Webster mice and the resulting litters screened for the 
transgene using the IL2TRANC/SHIVA1DN prim er pair which yields a 235 
bp  fragm ent (Table 2). Most did not differ significantly from the expected 1:1 
ratio of normahtransgenics. Forty of the line 12 F2 generation, the result of 
breeding F /s  to normals, also displayed the expected normal to transgenic 
ratio (Figure 8). Two groups of progeny dem onstrated possible germ  line
Table 2. Results of screening of F, generation from breeding of founders to 
norm al m ates
Founder N o Sex N o of Progeny No. Transgenics Differ8
3 F 10 4
12 M 8 4
23 F 17 2 *
27 M 11 3
42 M 19 8
60 M 5 2
61 F 13 2 *
73 F 13 4
aThose ratios of normal:transgenic progeny which differed (P<.05) from the 
expected 1:1 as determined by x2 analysis are indicated by an asterisk.
lanes 1 4 8 12 16 20 24
910 bp— ^  
540 bp :----------
lanes 25 28 32 36 40 44 48
Lane Discription__________________
1 0.15 pg pUC18 Ddel marker
2 PCR reaction (-) control
3 PCR reaction #3 DNA
4-12 PCR reaction Line 12 Fj DNA
13 0.15 pg pUC18 Ddel marker
14 PCR reaction plLSHJ (+) control
15 PCR reaction (-) control
16-35 PCR reaction line 12 F1 DNA
36 PCR reaction pILSHI (+) control
37 0.15 pg pUC18 Ddel marker
38-48 PCR reaction Line 12 F1 DNA
Figure 8. Results of tail tissue DNA PCR amplification of offspring from 
matings of Line 12 Fj Shiva 1 positive and founder animals to normal 
FVB/N mice. The IL2TRANC/SHIVA1DN prim er pair used for this 
screening amplifies a 235 bp  fragment of the transgene. Lanes are num ­
bered from left to right across the two gels. Lanes 1,13, and 37 were 
pUC18 Ddel m arkers w ith fragments of the sizes shown. Lanes 2 and 15 
were no-template negative controls. Lanes 14 and 36 were pILSHI-tem- 
plate positive controls. Lane 3 was amplified genomic DNA from founder 
#3, also as a positive control. The remaining 40 lanes were amplified DNA 
from 40 line 12 offspring; 18 of the 40 amplified a 235 bp band representing 
the IL2/Shiva 1 gene from the start of transcription to the stop codon. 
Electrophoresis m edium  was a Relient System precast 1% SeaKem Gold, IX 
TBE, agarose gel containing 0.5 p g /m l ethidium  bromide (FMC). Lanes 
containing PCR products were loaded w ith 5 pi of the 100 pi reaction vol­
ume.
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mosacism. PCR of DNA from two of the offspring of Line 73 resulted in 
amplification of a fragment smaller than expected by approxim ately 400 bp 
indicating a possible deletion m utation from the interior of the gene. A 
second PCR using the IL2TRANC/SHIVA1DN prim er set (Figure 3) 
produced no fragm ent indicating that the deletion included the start of 
transcription.
Representatives of 15 lines plus norm al FVB/N and Swiss-W ebster 
strains were sacrificed to test for expression of IL2-Shiva 1 mRNA in ConA- 
induced spleen-derived lymphocytes (Figure 9). RT-PCR analysis revealed 
two lines, Line 3 and Line 12, dem onstrating induced mRNA expression.
No specific PCR product was detected in the negative controls. In Line 3, no 
PCR product was detected when the cells were not exposed to Con A bu t a 
strong band was detected after induction. This is in agreem ent w ith the tight 
control docum ented for other genes controlled by the IL2 
prom oter/enhancer (Novak et al., 1990b, Emilie et al., 1989). However, in 
Line 12, although there was an increase in PCR product upon induction, 
some Shiva 1 mRNA was produced in lymphocytes not exposed to ConA, 
an indication of in vivo induction.
ConA especially at 3.25 p g /m l is not considered to be a strong inducer 
of IL2 expression yet a definite mRNA induction was m easured in these two 
lines. Concentrations as high as 25 pg /m l have been used on T cell 
lym phom as to induce maximal expression of IL2 enhancer-controlled 
reporter genes (Gillis et al., 1980; Fujita et al., 1986; Emilie et al., 1989).
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0.56 pg pBR322 Haelll marker 
PCR: No template (-) control 
PCR: FVB/N, MH3 primers 
PCR: FVB/N 
PCR: pILSHI (+) control 
PCR: Line 3 
PCR: Line 12
0.15 pg pUC18 Ddel marker
Lane  Lane Discripfon
1 .    elll r  1 & 13 0.15 pg pUC18 Ddel marker
2 & 14 PCR: pILSHI (+) control
3 & 15 RT-PCR: No template (-) control
4 & 16 RT-PCR: FVB/N resting
5 & 17 RT-PCR: FVB/N induced with ConA
6 & 18 RT-PCR: Line 3 resting
7 & 19 RT-PCR: Line 3 induced with ConA
8 & 20 RT-PCR: Line 12 resting
9 & 21 RT-PCR: Line 12 induced with ConA
10 & 22 RT-PCR: Line 73 resting
11 & 23 RT-PCR: Line 73 induced with ConA
12 & 24 BLANK
Figure 9. Results of PCR screening of Lines 3,12, and 73 both for the pres­
ence of DNA and RNA. Primer pair was IL2TRANC/SHIVA1DN unless 
otherwise noted. Gel m edium  was 1.5% agarose 0.5X TBE stained after elec­
trophoresis w ith a solution of 1 p g /m l ethidium  bromide. White arrows 
and numbers identify lanes. A: PCR products generated by amplification of 
DNA extracted from tail tissue using IL2TRANC/SHIVA1DN prim er pair 
summarizing the tail screening data. Lines 3 and 12 (lanes 6 and 7, respec­
tively) were positive. A fragm ent of FVB/N DNA was amplified w ith MH3 
prim er pair (lane 3) but not w ith IL2TRANC/SHIVA1DN prim er pair (lane 
4). Lane 2 was the no-template negative control, lane 1 the pBR322 Haelll 
size marker, and lane 8 the pUC18 Ddel size marker. Bj: PCR products gen­
erated by amplification of reverse transcribed total RNA from lymphocytes 
that were either resting or induced to produce IL2 using ConA. No 
detectable product was formed from Line 3 w hen not exposed to ConA 
(lane 6) but a strong band of the predicted 123 bp was found when RNA 
was extracted after 24 h  exposure to the mitogen (lane 7). Line 12 unin­
duced lymphocytes were found to have a low level of expression implying 
in vivo induction (lane 8) bu t that level increased upon 24 h exposure to 
ConA (lane 9). B2: Parallel reactions to those in B2 bu t w ithout reverse tran­
scriptase. There was no detectable product from any of the RNA extractions 
indicating no contaminating DNA in the preparations.
How ever, Gillis et al. (1980) reported only 4% of LBRM-33 cells rem ained 
viable after treatm ent w ith 20 (ig/m l ConA. In contrast, 87% rem ained 
viable at 2 (ig/m l. The ten-fold increase in ConA resulted in a 48.9-fold 
increase in IL2 activity. Of the mitogens tested (phytohem aglutinin-A  
(PHA), ConA, and phorbol myristate acetate (PMA) and com binations of 
these), only ConA at 2 p g /m l and PHA at 0.1% induced some activity while 
allowing over 87% of the cells to remain viable. It w as a concern that 
expression of Shiva 1 w ould be toxic to the lymphocytes and that 
stim ulation w ith lethal concentrations of ConA w ould m ask that effect. 
Therefore, it was determ ined that a low but still effective dose of ConA 
w ould be used and no effort was m ade to titer ConA stim ulation maximize 
induction of IL2. No apparent adverse effects were noted in any of the 
lymphocyte cultures, including controls, w ith the low level of ConA used.
The reason for the uninduced expression in Line 12 was not 
investigated. It is likely that some activated T cells were present in the 
culture before addition of ConA. This implies that the gene was induced in 
vivo in response to natural stimulus even though the cells had  been in 
culture for over 48 h, time enough for term ination of native IL2 expression. 
H ow ever, native IL2 expression is controlled not only at the transcriptional 
level bu t also by rapid mRNA degradation signaled by elements in  the 3' 
untranslated  region upon removal of cytokine-inducing stim uli (Mather, 
1989; Troutt and  Kelso, 1992). This region was om itted in 1L2-Shiva 1 and  
replaced w ith SV40 sequence which should lengthen the half life of the
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transcript over that of native IL2. If Shiva 1 transcription was the result of 
in vivo induction, it w ould m ean that helper T cell targeted expression of a 
transgene in vivo is possible using the IL2 prom oter/enhancer at least when 
linked to Shiva 1 and the SV40 polyadenylation signal.
However, induction and level of expression of stably integrated 
transgenes is unpredictable. Configuration of the chromosome at the site of 
integration, copy num ber of the transgene, and flanking sequences m ay all 
play a role. A lthough the known specific controlling regions of m ouse IL2 
w ere included in the gene, interaction with the site of integration m ay have 
resulted in low level expression in Line 12 in the absence of any stimulation. 
An assay for IL2 levels w ould have been valuable at this point as a 
determ inant of the extent T cell activation in the absence of ConA.
Dot blot antibody detection of Shiva 1 in supernatant and  crude cell 
lysate of induced lymphocytes was unsuccessful. Excessive background 
especially for cultures grown in Lymphocyte Culture Fluid (Torres et al., 
1993) prevented definitive results. Supply of antibody was very limited 
pu tting  some constraints on developm ent of efficient m ethodology and 
attem pts by F.M. Enright to produce additional antibody have been 
unsuccessful (personnel communication). The lower lim it of detection was 
125 ng of Shiva 1 or the equivalent of 80 nM.
U npublished data (F.M. Enright, personal comm unication) indicates 
that lytic activity is associated w ith difficulty in detection of peptide w ith 
antibody w hen expressed as genes in fish, whereas, inactive peptide is
readily detected in baculovirus insect systems. It has been dem onstrated that 
the am phipathic a-helix of apolipoprotein, melittin, and cecropin A interact 
strongly w ith cell mem branes and this interaction is vital to activity. 
Antibody against Shiva 1 was generated from synthesized peptide. It is 
possible that hapten necessary for antibody binding is unavailable in active 
Shiva 1 due to competition by membrane proteins whereas inactive peptide 
is free to associate w ith antibody. This m ay not be the case, however, in 
plants. Jaynes et al. (1993) documented the presence of Shiva 1 peptide by 
western blot in tobacco plants w ith enhanced disease resistance.
CONCLUDING REMARKS
These results do not m ark an end but a beginning; they are the first 
steps in  investigating the targeted expression of a cecropin. The prom ise of 
these broad spectrum  antimicrobials is enormous. They can destroy 
transform ed cells, enveloped viruses, and m any protozoan and bacterial 
pathogens including obligate intracellular parasites yet are non-toxic to 
norm al healthy cells at concentrations >10 times that needed for lytic activity 
against bacteria. Their small size m ake them easy to synthesize to 
investigate the impact that small changes in aa composition will have on 
specificity and activity against specific cells. The small size also allows 
synthesis of genes for novel peptides whose toxicity and lytic activity m ay be 
tailored for specific targeted expression systems.
The germ-line transgenic mouse is just a m odel useful for evaluating 
the effectiveness and safety of the cecropins when expressed in lymphocytes. 
If these are shown to be satisfactory, the possibilities become endless. As 
more is learned about enhancers, expression m ay be targeted to m acrophages 
for activity earlier in  the im m une response or to platelets for release at the 
site of a w ound. Tumor infiltrating lymphocytes, already studied  as a 
vehicle for targeting toxins like tumor-necrosis factor to m alignant tum ors, 
m ay be engineered to deliver cecropins. Diseases such as m alaria and 
brucellosis, which have been difficult to control, m ay be susceptible to gene 
therapy using cecropins. Domestic animals could be m ade generally m ore 
disease resistant allowing a reduction in the use of antibiotics, which may, in
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turn, retard bacterial evolution toward resistance to these valuable 
therapeutics.
In addition, this research has proven the feasibility of targeting 
expression of a synthetic gene to lymphocytes even if lytic peptides do not 
live u p  to their promise. Lymphocyte targeted expression alone could have 
broad application in immunology and medicine using other synthetic or 
natural genes.
The research w ith the transgenic lines continues. There are currently 
19 individuals from Line 12 being tested against FV B/N norm al mice and 
Line 73 mice in Dr. Frederick Enright's laboratory at Louisiana State 
University for resistance to Brucella abortus. Several litters have been born 
w ithin the past m onth from both Line 3 and Line 12 parents and detection of 
active peptide in lymphocyte cell lysate and supernatant will be pursued.
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APPENDIXES
PRIMARY AND SECONDARY STRUCTURE OF 
SHIVA 1 AND CECROPIN B
RESTRICTION MAP OF pILSHIX
RESTRICTION MAP OF pILSHIX/neo
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Restriction Map of pILSHIX 
4471 base pairs
Derived from pILSHI (from pUC18) and pMSG via pSL1190
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Restriction Map of pILSHIX/neo 
5605 bp
Derived from pILSHIX and neo cassette from pMCIneoPolyA
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